TG Therapeutics, Inc. (TGTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on January 13, 2026. The filing serves as a Regulation FD disclosure to announce the release of a press release regarding preliminary financial results and future guidance.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) that contains preliminary fourth quarter and full year 2025 net product revenue figures, as well as 2026 revenue guidance. As the full text of the press release is not included in the provided input, these specific financial metrics are not available for summary.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It indicates that such information, including anticipated development milestones, is contained within the referenced press release.
Guidance, Outlook, and Risks
Management has issued preliminary guidance for 2026 revenue and provided updates on anticipated development milestones. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific preliminary Q4 and full-year 2025 net product revenue numbers.
- Verify the specific 2026 revenue guidance range provided in the press release.
- Confirm the details of the anticipated development milestones mentioned in the announcement.
- Check subsequent filings for the official incorporation of this guidance into audited financial statements.